Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 2.29% is 44% below its 4-year average of 4.10%, near the low end of its 4-year range (0.22%–13156.68%).
As of the fiscal period ended Tuesday, June 30, 2026. 15.08% above its 12-month average of 1.99%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 2.29%.
DEBT TO ASSETS RATIO
2.29%
DEBT TO ASSETS RATIO AVG TTM
1.99%
DEBT TO ASSETS RATIO AVG 3Y
2.64%
DEBT TO ASSETS RATIO AVG 5Y
N/A
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+15.08%
CURRENT VS 3Y AVG
-13.28%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 873 covered companies
CURRENT VS SECTOR MEDIAN
+2441.26%
vs the sector median at left
Mangoceuticals, Inc.
Market Cap
$7.64M
Debt to Assets Ratio
2.29%
TTM Avg
1.99%
3Y Avg
2.64%
5Y Avg
N/A
Market Cap
$7.62M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.67M
Debt to Assets Ratio
0.05%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.75M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.87M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.31M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Mangoceuticals, Inc. (MGRX) | $7.64M | 2.29% | 1.99% | 2.64% | N/A |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.62M | 0.00% | N/A | N/A | N/A |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.67M | 0.05% | N/A | N/A | N/A |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.75M | 0.00% | N/A | N/A | N/A |
| Aprea Therapeutics, Inc. (APRE)vs › | $7.87M | 0.00% | N/A | N/A | N/A |
| Traws Pharma, Inc. (TRAW)vs › | $7.92M | 0.00% | N/A | N/A | N/A |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | 0.00% | N/A | N/A | N/A |
| GT Biopharma, Inc. (GTBP)vs › | $8.04M | 0.00% | N/A | N/A | N/A |
| DataMEDS AI, Inc. (MEDS)vs › | $8.05M | 1.00% | N/A | N/A | N/A |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.19M | 0.17% | N/A | N/A | N/A |
Debt/Assets
2.3%
Debt/Equity
0.03
Current Ratio
0.18
Interest Coverage
-185.1x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 2.29% |
| 2026-03-31 | 2.03% |
| 2025-12-31 | 1.91% |
| 2025-09-30 | 0.68% |
| 2025-06-30 | 3.02% |
| 2025-03-31 | 0.22% |
| 2024-12-31 | 1.40% |
| 2024-09-30 | 1.82% |
| 2024-06-30 | 1.87% |
| 2024-03-31 | 66.60% |
| 2023-12-31 | 12.25% |
| 2023-09-30 | 8.99% |
| 2023-06-30 | 4.78% |
| 2023-03-31 | 6.34% |
| 2022-12-31 | 35.17% |
| 2022-09-30 | 9.76% |
| 2022-06-30 | 13156.68% |
